dm+d

Unassigned

New Medicines

Primary biliary cholangitis (PBC) and other cholestastic liver diseases-associated pruritus - with inadequate response to colestyramine

Information

New molecular entity
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

An ileal sodium-dependent bile acid transporter inhibitor
The prevalence of PBC has been estimated as 12.9 per 100,000 population in the UK with up to 90% of cases occurring in women. Around 55% report pruritus and in 10% this is severe. It is usually assumed to be due to deposition of bile pigments in skin although evidence is lacking and it may be due to central opioid neurotransmission [1].
Primary biliary cholangitis (PBC) and other cholestastic liver diseases-associated pruritus - with inadequate response to colestyramine
Oral